| Description: |
MM41 is a quadruplex-interactive compound which binds strongly to the quadruplexes encoded in the promoter sequences of the BCL-2 and k-RAS genes, both of which are dis-regulated in many human pancreatic cancers. MM41has significant in vivoanti-tumour activity against the MIA PaCa-2 pancreatic cancer xenograft model. IV administration with a twice-weekly 15 mg/kg dose produces ca 80% tumour growth decrease in a group of tumour-bearing animals. Two animals survived tumour-free after 279 days. High levels of MM41 are rapidly transported into cell nuclei and were found to accumulate in the tumour. Levels of BCL-2 were reduced by ca 40% in tumours from MM41-treated animals relative to controls, consistent with BCL-2 being a target for MM41. Molecular modelling suggests that MM41 binds to a BCL-2 quadruplex in a manner resembling that previously observed in co-crystal structures with human telomeric quadruplex. MM41 (and by implication other quadruplex-targeting small molecules) can bind to quadruplex-forming promoter regions in a number of genes and down-regulate their transcription. For the detailed information of MM-41, the solubility of MM-41 in water, the solubility of MM-41 in DMSO, the solubility of MM-41 in PBS buffer, the animal experiment (test) of MM-41, the cell expriment (test) of MM-41, the in vivo, in vitro and clinical trial test of MM-41, the EC50, IC50,and affinity,of MM-41, For the detailed information of MM-41, the solubility of MM-41 in water, the solubility of MM-41 in DMSO, the solubility of MM-41 in PBS buffer, the animal experiment (test) of MM-41, the cell expriment (test) of MM-41, the in vivo, in vitro and clinical trial test of MM-41, the EC50, IC50,and affinity,of MM-41, Please contact DC Chemicals. |
